Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. a systematic review

Basic and Clinical Pharmacology and Toxicology

Volumn 116, Issue 4, 2015, Pages 315-320

  Ennis, Zandra Nymand ^a   Damkier, Per ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ANKYLOBLEPHARON; ARTICLE; ATRIOVENTRICULAR CANAL; CLUBFOOT; CONGENITAL MALFORMATION; DRUG EXPOSURE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MENINGOCELE; PREGNANCY OUTCOME; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ABNORMALITIES, DRUG-INDUCED; ADULT; META ANALYSIS; PREGNANCY; PREGNANCY COMPLICATIONS; SCHIZOPHRENIA;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BENZODIAZEPINES; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; QUETIAPINE FUMARATE; RISPERIDONE; SCHIZOPHRENIA;

EID: 84924807245     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12372     Document Type: Article

References (66)

1. Abel KM. Fetal antipsychotic exposure in a changing landscape: seeing the future. Br J Psychiatry 2013;202:321-3.
2. Antenatal and Postnatal Mental Health. http://www.nice.org.uk (last accessed on 27 May 2014).
3. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011;25:567-620.
4. World Federation of Societies of Biological Psychiatry. http://www.wfsbp.org (last accessed on 3 June 2014).
5. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111:1001-20.
6. Olanzapine UK SPC. Datapharm Communications LTD; https://www.medicines.org.uk (last accessed on 3 June 2014).
7. Quetiapine UK SPC. Datapharm Communications LTD; https://www.medicines.org.uk (last accessed on 3 June 2014).
8. Risperidone UK SPC. Datapharm Communications LTD; https://www.medicines.org.uk (last accessed on 3 June 2014).
9. Aripiprazole UK SPC. Datapharm Communications LTD; https://www.medicines.org.uk7 (last accessed on 3 June 2014).
10. Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4-10.
11. Toh S, LIi Q, Cheetham TC et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585, 615 deliveries. Arch Womens Ment Health 2013;16:149-57.
12. Danish olanzapine, quetiapine, risperione and aripiprazole sale 2009-2013. [SSI, The Danish Ministry of Health] http://www.medstat.dk (last accessed on 3 June 2014).
13. Mcgrath JJ. Variations in the incidence of schizophrenia: data versus dogma. Schizophr Bull 2006;32:195-7.
14. PRISMA statement. Preferred reporting items for systematic reviews and meta-analyses; 2014. http://www.prisma-statement.org (last accessed on 27 May 2014).
15. The Swedish Birth Registry. http://www.janusinfo.se (last accessed on 27 May 2014).
16. Kallen B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013;6:1221-86.
17. Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28:279-88.
18. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
19. Schardein JL. Chemically Induced Birth Defects, 3rd edn. Marcel Dekker INC, New York, NY, 2000.
20. Oakley GP Jr. Frequency of human congenital malformations. Clin Perinatol 1986;13:545-54.
21. Habermann F, Fritzsche J, Fuhlbruck F et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 2013;33:453-62.
22. Tenyi T, Nagy A, Herold R, Fekete S. Extended release quetiapine fumarate and pregnancy. Neuropsychopharmacol Hung 2013;15:49-50.
23. Grover S, Madan R. Successful use of quetiapine in two successive pregnancies. J Neuropsy Clin Neurosci 2012;24:E38.
24. Klier CM, Mossaheb N, Saria A, Schloegelhofer M, Zernig G. Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. J Clin Psychopharmacol 2007;27:720-2.
25. Gentile S. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding. Arch Womens Ment Health 2006;9:158-9.
26. Tenyi T, Trixler M, Keresztes Z. Quetiapine and pregnancy. Am J Psychiatry 2002;159:674.
27. Mendhekar D, Lohia D. Risperidone therapy in two successive pregnancies. J Neuropsy Clin Neurosci 2008;20:485-6.
28. Wichman CL. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health 2009;12:53-7.
29. Rodriguez-Salgado B. Risperidone safety in pregnancy. A case report. Actas Esp Psiquiatr 2008;36:366-8.
30. Dabbert D, Heinze M. Follow-up of a pregnancy with risperidone microspheres. Pharmacopsychiatry 2006;39:235.
31. Kim SW, Kim KM, Kim JM et al. Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:543-5.
32. Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period. J Clin Psychiatry 2002;63:76-7.
33. Widschwendter CG, Hofer A. Aripiprazole use in early pregnancy: a case report. Pharmacopsychiatry 2012;45:299-300.
34. Gentile S, Tofani S, Bellantuono C. Aripiprazole and pregnancy: a case report and literature review. J Clin Psychopharmacol 2011;31:531-2.
35. Nguyen T, Teoh S, Hackett LP, Ilett K. Placental transfer of aripiprazole. Aust N Z J Psychiatry 2011;45:500-1.
36. Lutz UC, Hiemke C, Wiatr G, Farger G, Arand J, Wildgruber D. Aripiprazole in pregnancy and lactation: a case report. J Clin Psychopharmacol 2010;30:204-5.
37. Mervak B, Collins J, Valenstein M. Case report of aripiprazole usage during pregnancy. Arch Womens Ment Health 2008;11:249-50.
38. Mendhekar DN, Sunder KR, Andrade C. Aripiprazole use in a pregnant schizoaffective woman. Bipolar Disord 2006;8:299-300.
39. Spyropoulou AC, Zervas IM, Soldatos CR. Hip dysplasia following a case of olanzapine exposed pregnancy: a questionable association. Arch Womens Ment Health 2006;9:219-22.
40. EUROCAT guide 1.3 and reference documents 2014. http://www.eurocat-network.eu (last accessed on 27 May 2014).
41. Arora M, Praharaj SK. Meningocele and ankyloblepharon following in utero exposure to olanzapine. Eur Psychiatry 2006;21:345-6.
42. Yeshayahu Y. The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities. Am J Psychiatry 2007;164:1759-60.
43. Peng M, Gao K, Ding Y et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology 2013;228:577-84.
44. Manakova E, Hubikova L. Antidepressant drug exposure during pregnancy. CZTIS small prospective study. Neuro Endocrinol Lett 2011;32(Suppl 1):53-6.
45. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000;20:399-403.
46. Mckenna K, Koren G, Tetelbaum M et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005;66:444-9; quiz 546.
47. Brunner E, Falk DM, Jones M, Dey DK, Shatapthy CC. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol 2013;14:38.
48. Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open 2013;3:10.
49. Kulkarni J, Worsley R, Gilbert H et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS ONE 2014;9:e94788.
50. Olanzapin; The Swedish Birth Registry. http://www.janusinfo.se (last accessed on 3 June 2014).
51. Twaites BR, Wilton LV, Shakir SA. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England. J Psychopharmacol 2007;21:392-9.
52. Yaris F, Ulku C, Kesim M et al. Psychotropic drugs in pregnancy: a case-control study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:333-8.
53. Quetiapin; The Swedish Birth Registry. [http://www.janusinfo.se (last accessed on 3 June 2014).
54. Coppola D, Russo LJ, Kwarta RF Jr, Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007;30:247-64.
55. Risperidon; The Swedish Birth Registry. http://www.janusinfo.se (last accessed on 3 June 2014).
56. Aripiprazol; The Swedish Birth Registry. http://www.janusinfo.se (last accessed on 3 June 2014).
57. Guideline on risk assessment of medical products on human reproduction and lactation: from data to labelling. European Medicines Agency; http://www.ema.europa.eu (last accessed on 2 June 2014).
58. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62.
59. Asmal L, Flegar SJ, Wang J, Rumel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2013;11:CD006625.
60. Buckley PF, Corell CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008;69(Suppl 1):4-17.
61. Tandorn R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry 2011;72(Suppl 1):4-8.
62. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol 2007;22:249-67.
63. Vares M, Saetre P, Stralin P, Levander S, Lindstrom E, Jonsson EG. Concomitant medication of psychoses in a lifetime perspective. Hum Psychopharmacol 2011;26:322-31.
64. Zink M, Englisch S, Meyedr-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010;23:103-11.
65. Chakos M, Patel JK, Rosenheck R et al. Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study. Clin Schizophr Relat Psychoses 2011;5:124-34.
66. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK, Afzal S, Gislason GH, Torp-Pedersen C, Poulsen HE. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open. 2012 Jun 18;2:(3).